https://apnews.com/01332124d4c18aba556a53b1a57bcc84

LONDON (AP) — AstraZeneca's release Monday of encouraging data about its coronavirus vaccine from its U.S. trial raised hopes that the drug company could bury doubts about the shot and put a troubled rollout behind it. But hours later, U.S. officials issued an unusual statement expressing concerns the company had included “outdated information” from its study and that it may have provided “an incomplete view of the efficacy data.”

A company spokesman said Tuesday it was “looking into it.”